Literature DB >> 17905102

Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperplasia.

Philip M Ullrich1, Susan K Lutgendorf, Karl J Kreder.   

Abstract

OBJECTIVES: The sympathetic nervous system and hypothalamic-pituitary-gonadal axis are involved in the pathophysiology of benign prostatic hyperplasia (BPH). The sympathetic nervous system and hypothalamic-pituitary-gonadal axis are also highly reactive to psychological stressors, yet associations between prostate function and reactivity to a psychological stressor have not been examined using standardized psychological stress paradigms. The objective of this study was to examine the associations between psychological stress reactivity and BPH disease parameters.
METHODS: A total of 83 men diagnosed with BPH completed a standardized laboratory stress task, yielding measures of blood pressure, testosterone, and cortisol reactivity. Links were examined between stress reactivity (as indicated by changes in blood pressure, testosterone, and cortisol during the stress task) and measures of BPH disease, including prostate volume, postvoid residual bladder volume, urine flow rate, self-reported lower urinary tract symptoms, and impact and bother scores.
RESULTS: In equations controlling for BPH medications, body mass index, and age, greater diastolic blood pressure reactivity was associated with a greater transition zone volume (P <0.001), greater total prostate gland volume (P <0.05), greater postvoid residual bladder volume (P <0.05), more severe lower urinary tract symptoms (P <0.001), and greater impact scores (P <0.05). Greater cortisol reactivity was associated with greater bother (P <0.05) and impact (P <0.001) scores.
CONCLUSIONS: Physiologic reactivity to a standardized laboratory stressor is associated with objective and subjective BPH disease parameters. These findings contribute to growing data suggesting that stress conditions could be associated with the development or aggravation of prostatic disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17905102      PMCID: PMC2084069          DOI: 10.1016/j.urology.2007.04.048

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  27 in total

1.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

2.  Premenopausal and postmenopausal women differ in their cardiovascular and neuroendocrine responses to behavioral stressors.

Authors:  P G Saab; K A Matthews; C M Stoney; R H McDonald
Journal:  Psychophysiology       Date:  1989-05       Impact factor: 4.016

Review 3.  Body fat distribution, insulin resistance, and metabolic diseases.

Authors:  P Björntorp
Journal:  Nutrition       Date:  1997-09       Impact factor: 4.008

Review 4.  Salivary cortisol in psychoneuroendocrine research: recent developments and applications.

Authors:  C Kirschbaum; D H Hellhammer
Journal:  Psychoneuroendocrinology       Date:  1994       Impact factor: 4.905

5.  Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.

Authors:  J Hammarsten; B Högstedt
Journal:  Eur Urol       Date:  2001-02       Impact factor: 20.096

6.  Stress, hostility, and disease parameters of benign prostatic hyperplasia.

Authors:  Philip M Ullrich; Susan K Lutgendorf; Jane Leserman; Derek G Turesky; Karl J Kreder
Journal:  Psychosom Med       Date:  2005 May-Jun       Impact factor: 4.312

7.  Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.

Authors:  Garry Welch; Katie Weinger; Michael J Barry
Journal:  Urology       Date:  2002-02       Impact factor: 2.649

8.  The role of psychological coronary risk factors in insulin and glucose metabolism.

Authors:  K Räikkönen; L Keltikangas-Järvinen; A Hautanen
Journal:  J Psychosom Res       Date:  1994-10       Impact factor: 3.006

Review 9.  The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis.

Authors:  G P Chrousos; P W Gold
Journal:  JAMA       Date:  1992-03-04       Impact factor: 56.272

Review 10.  Abdominal obesity and the metabolic syndrome.

Authors:  P Björntorp
Journal:  Ann Med       Date:  1992-12       Impact factor: 4.709

View more
  10 in total

Review 1.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

Review 2.  Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Authors:  Linda Vignozzi; Mauro Gacci; Mario Maggi
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

3.  Measures of autonomic nervous system activity and lower urinary tract symptoms.

Authors:  Jennifer L St Sauver; Paola Sandroni; Debra J Jacobson; Michaela E McGree; Michael M Lieber; Steven J Jacobsen
Journal:  Clin Auton Res       Date:  2010-09-16       Impact factor: 4.435

4.  Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection.

Authors:  Tiago Gorgal; Ana Charrua; João F Silva; António Avelino; Paulo Dinis; Francisco Cruz
Journal:  BMC Urol       Date:  2012-01-04       Impact factor: 2.264

5.  Depression is a major risk factor for the development of dementia in people with lower urinary tract symptoms: A nationwide population-based study.

Authors:  Ming-Jung Ou; Chun-Che Huang; Yi-Chi Wang; Yung-Liang Chen; Chung-Han Ho; Ming-Ping Wu; Yu-Tung Huang; Chien-Yi Wu; Ping-Jen Chen
Journal:  PLoS One       Date:  2019-06-07       Impact factor: 3.240

Review 6.  Lower urinary-tract symptoms and testosterone in elderly men.

Authors:  Aksam A Yassin; Ahmed I El-Sakka; Farid Saad; Louis J G Gooren
Journal:  World J Urol       Date:  2008-07-02       Impact factor: 4.226

7.  Association of a Missense ALDH2 Single Nucleotide Polymorphism (Glu504Lys) With Benign Prostate Hyperplasia in a Korean Population.

Authors:  Hosik Seok; Koo Han Yoo; Young Ock Kim; Joo-Ho Chung
Journal:  Int Neurourol J       Date:  2013-12-31       Impact factor: 2.835

Review 8.  Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options.

Authors:  Farid Saad; Aksam A Yassin; Ahmad Haider; Louis Gooren
Journal:  Arab J Urol       Date:  2011-09-09

9.  Effect of pulsed electromagnetic field therapy on prostate volume and vascularity in the treatment of benign prostatic hyperplasia: a pilot study in a canine model.

Authors:  Raffaella Leoci; Giulio Aiudi; Fabio Silvestre; Elaine Lissner; Giovanni Michele Lacalandra
Journal:  Prostate       Date:  2014-06-09       Impact factor: 4.104

10.  Psychopharmacological effects of riparin III from Aniba riparia (Nees) Mez. (Lauraceae) supported by metabolic approach and multivariate data analysis.

Authors:  Sócrates Golzio Dos Santos; Isis Fernandes Gomes; Adriana Maria Fernandes de Oliveira Golzio; Augusto Lopes Souto; Marcus Tullius Scotti; Josean Fechine Tavares; Stanley Juan Chavez Gutierrez; Reinaldo Nóbrega de Almeida; José Maria Barbosa-Filho; Marcelo Sobral da Silva
Journal:  BMC Complement Med Ther       Date:  2020-05-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.